X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DARVIAS® (darinaparsin), an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.
Lead Product(s): Darinaparsin
Therapeutic Area: Oncology Product Name: Darvias
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nippon Kayaku
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
DARVIAS (darinaparsin), an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.
Lead Product(s): Darinaparsin
Therapeutic Area: Oncology Product Name: Darvias
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Brand Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
DARVIAS® (DARINAPARSIN), an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors.
Lead Product(s): Darinaparsin
Therapeutic Area: Oncology Product Name: Darvias
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Details:
Under the license agreement, Solasia and Nippon Kayaku will make further efforts to provide a new treatment option to patient suffering from PTCL and for marketing rights to darinaparsin.
Lead Product(s): Darinaparsin
Therapeutic Area: Oncology Product Name: SP-02
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Nippon Kayaku
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 26, 2021
Details:
The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market for arfolitixorin.
Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Isofol Medical
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 13, 2020
Details:
The primary endpoint (antitumor effect) was achieved. No new safety concerns were identified in the safety analysis. This study was conducted as the final registration trial for the indication of relapsed or refractory PTCL. Solasia begins preparing for the NDA Filing.
Lead Product(s): Darinaparsin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
